PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

ClinicalTrials.gov ID: NCT00087633

Public ClinicalTrials.gov record NCT00087633. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 6:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-label Study of Prophylactic Administration of PEGASYS Plus Ribavirin After Liver Transplantation on Hepatitis C Recurrence in Patients With Hepatitis C

Study identification

NCT ID: NCT00087633
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 115 participants

Conditions and interventions

Conditions

Hepatitis C, Chronic

Interventions

Copegus Drug
peginterferon alfa-2a [Pegasys] Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2004
Primary completion: Sep 30, 2008
Completion: Sep 30, 2008
Last update posted: Mar 28, 2018

2004 – 2008

United States locations

U.S. sites: 28
U.S. states: 20
U.S. cities: 25

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294	—
Not listed	Phoenix	Arizona	85054	—
Not listed	Los Angeles	California	90095-1749	—
Not listed	San Francisco	California	94115	—
Not listed	San Francisco	California	94143	—
Not listed	Aurora	Colorado	80045	—
Not listed	Gainesville	Florida	32610-0214	—
Not listed	Jacksonville	Florida	32216	—
Not listed	Miami	Florida	33136-1051	—
Not listed	Chicago	Illinois	60611	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Baltimore	Maryland	21205	—
Not listed	Burlington	Massachusetts	01805	—
Not listed	Minneapolis	Minnesota	55455	—
Not listed	Rochester	Minnesota	55905	—
Not listed	St Louis	Missouri	63110	—
Not listed	Omaha	Nebraska	68198-3285	—
Not listed	Newark	New Jersey	07101-1709	—
Not listed	New York	New York	10016	—
Not listed	New York	New York	10029	—
Not listed	Cincinnati	Ohio	45267	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Philadelphia	Pennsylvania	19141	—
Not listed	Nashville	Tennessee	37232	—
Not listed	Dallas	Texas	75246	—
Not listed	San Antonio	Texas	78284	—
Not listed	Seattle	Washington	98195	—
Not listed	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00087633, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 28, 2018 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00087633 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →